

December 10, 2020
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Commencement of in-house sales of the anti-cancer agent Treakisym®

TOKYO, Japan, December 10, 2020 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") today announced that its license agreement for the co-development and commercialization of bendamustine hydrochloride in Japan with Eisai Co., Ltd. for the anticancer agent TREAKISYM® expired on December 9, 2020, and that Symbio began sales through its own sales organization in Japan today.

Since its founding in March 2005, Symbio has aimed to evolve into a specialty pharmaceutical company with a fully integrated sales operation. Symbio decided in October 2018 to transition to in-house sales, as we believe that accurate communication of product information to healthcare professionals will maximize business potential and value to shareholders. After two years of preparation, Symbio began operation of its nationwide sales system today.

A total of 62 medical representatives with extensive sales experience and highly specialized expertise in the hematology field have been assigned to major regions throughout the country. At the same time, the Company established a Regulatory Affairs & Quality Assurance Division to further strengthen the stable supply and quality assurance of products. In addition, Symbio has established a nationwide distribution system in collaboration with the Suzuken Group and the Kyoso Mirai Group as sole distributors, with two distribution centers, one in Eastern Japan and one in Western Japan, and a partnership with S.D. Collabo Co., Ltd.

Statement from Fuminori Yoshida, President and CEO of Symbio: "We will achieve profitability as the first step in our second inauguration by transitioning to a company with its own sales and marketing force, and the moment has come to transform from an R&D-oriented venture to a full-fledged pharmaceutical company, maximizing the potential of our products."

Symbio does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2020.

Contact

Investor Relations

Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® was approved for the additional indications of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- SymBio achieved the primary endpoint (overall response rate) in Phase III study of TREAKISYM® in combination with rituximab as treatment for r/r DLBCL and submitted a partial change application with respect to its marketing approval in May 2020.
- TREAKISYM® ready-to-dilute ("RTD") liquid formulation was approved in Japan in September 2020.
- SymBio aims to achieve annual sales of JPY 10 billion on a NHI drug price basis at the earliest possible stage.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.